HER1/EGFR Targeting: Refining the Strategy

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Human epidermal growth factor receptor (EGFR), HER, targeting has formed the basis of extensive and growing drug development programs in various companies. However, receptor biology is often poorly explained and confusing. The HER family of four naturally occurring receptors and one tumor-specific mutant can activate signaling via a complex and sophisticated range of mechanisms, which we are only beginning to understand. HER1/EGFR downstream signaling can lead to tumor growth and development via a host of processes, including enhanced cellular proliferation, survival, and metastasis. A range of potential therapeutic targets exists within the HER signaling system, both inside and outside the cell. Monoclonal antibodies and tyrosine kinase inhibitors, acting extracellularly and intracellularly, respectively, comprise two classes of agents most advanced in clinical development or already available for use. Despite promising single-agent activity in chemotherapy-resistant patients with non-small cell lung cancer (NSCLC), disappointing results from two phase III trials of the tyrosine kinase inhibitor gefitinib in NSCLC have been of concern to some. However, many factors may have contributed to this outcome, and it is not necessarily predictive of the future usefulness of these agents. Patient characteristics, lack of patient selection, dosing schedule, and trial design may all have played roles. It is important to remember that intracellular targeting of HER is a relatively novel approach, and our knowledge of how best to optimize such treatment is still unfolding. More clinical experience is needed.

Original languageEnglish (US)
Pages (from-to)58-67
Number of pages10
JournalOncologist
Volume9
Issue number1
DOIs
StatePublished - 2004

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Growth and Development
Patient Selection
Neoplasms
Appointments and Schedules
Monoclonal Antibodies
Cell Proliferation
Neoplasm Metastasis
Drug Therapy
Survival
Therapeutics
Pharmaceutical Preparations
gefitinib

Keywords

  • Cancer
  • Erlotinib
  • Gefitinib
  • HER
  • Targeted therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

HER1/EGFR Targeting : Refining the Strategy. / Perez-Soler, Roman.

In: Oncologist, Vol. 9, No. 1, 2004, p. 58-67.

Research output: Contribution to journalArticle

@article{2fab494d11724646b8f1b8c77652abe0,
title = "HER1/EGFR Targeting: Refining the Strategy",
abstract = "Human epidermal growth factor receptor (EGFR), HER, targeting has formed the basis of extensive and growing drug development programs in various companies. However, receptor biology is often poorly explained and confusing. The HER family of four naturally occurring receptors and one tumor-specific mutant can activate signaling via a complex and sophisticated range of mechanisms, which we are only beginning to understand. HER1/EGFR downstream signaling can lead to tumor growth and development via a host of processes, including enhanced cellular proliferation, survival, and metastasis. A range of potential therapeutic targets exists within the HER signaling system, both inside and outside the cell. Monoclonal antibodies and tyrosine kinase inhibitors, acting extracellularly and intracellularly, respectively, comprise two classes of agents most advanced in clinical development or already available for use. Despite promising single-agent activity in chemotherapy-resistant patients with non-small cell lung cancer (NSCLC), disappointing results from two phase III trials of the tyrosine kinase inhibitor gefitinib in NSCLC have been of concern to some. However, many factors may have contributed to this outcome, and it is not necessarily predictive of the future usefulness of these agents. Patient characteristics, lack of patient selection, dosing schedule, and trial design may all have played roles. It is important to remember that intracellular targeting of HER is a relatively novel approach, and our knowledge of how best to optimize such treatment is still unfolding. More clinical experience is needed.",
keywords = "Cancer, Erlotinib, Gefitinib, HER, Targeted therapy, Tyrosine kinase inhibitors",
author = "Roman Perez-Soler",
year = "2004",
doi = "10.1634/theoncologist.9-1-58",
language = "English (US)",
volume = "9",
pages = "58--67",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - HER1/EGFR Targeting

T2 - Refining the Strategy

AU - Perez-Soler, Roman

PY - 2004

Y1 - 2004

N2 - Human epidermal growth factor receptor (EGFR), HER, targeting has formed the basis of extensive and growing drug development programs in various companies. However, receptor biology is often poorly explained and confusing. The HER family of four naturally occurring receptors and one tumor-specific mutant can activate signaling via a complex and sophisticated range of mechanisms, which we are only beginning to understand. HER1/EGFR downstream signaling can lead to tumor growth and development via a host of processes, including enhanced cellular proliferation, survival, and metastasis. A range of potential therapeutic targets exists within the HER signaling system, both inside and outside the cell. Monoclonal antibodies and tyrosine kinase inhibitors, acting extracellularly and intracellularly, respectively, comprise two classes of agents most advanced in clinical development or already available for use. Despite promising single-agent activity in chemotherapy-resistant patients with non-small cell lung cancer (NSCLC), disappointing results from two phase III trials of the tyrosine kinase inhibitor gefitinib in NSCLC have been of concern to some. However, many factors may have contributed to this outcome, and it is not necessarily predictive of the future usefulness of these agents. Patient characteristics, lack of patient selection, dosing schedule, and trial design may all have played roles. It is important to remember that intracellular targeting of HER is a relatively novel approach, and our knowledge of how best to optimize such treatment is still unfolding. More clinical experience is needed.

AB - Human epidermal growth factor receptor (EGFR), HER, targeting has formed the basis of extensive and growing drug development programs in various companies. However, receptor biology is often poorly explained and confusing. The HER family of four naturally occurring receptors and one tumor-specific mutant can activate signaling via a complex and sophisticated range of mechanisms, which we are only beginning to understand. HER1/EGFR downstream signaling can lead to tumor growth and development via a host of processes, including enhanced cellular proliferation, survival, and metastasis. A range of potential therapeutic targets exists within the HER signaling system, both inside and outside the cell. Monoclonal antibodies and tyrosine kinase inhibitors, acting extracellularly and intracellularly, respectively, comprise two classes of agents most advanced in clinical development or already available for use. Despite promising single-agent activity in chemotherapy-resistant patients with non-small cell lung cancer (NSCLC), disappointing results from two phase III trials of the tyrosine kinase inhibitor gefitinib in NSCLC have been of concern to some. However, many factors may have contributed to this outcome, and it is not necessarily predictive of the future usefulness of these agents. Patient characteristics, lack of patient selection, dosing schedule, and trial design may all have played roles. It is important to remember that intracellular targeting of HER is a relatively novel approach, and our knowledge of how best to optimize such treatment is still unfolding. More clinical experience is needed.

KW - Cancer

KW - Erlotinib

KW - Gefitinib

KW - HER

KW - Targeted therapy

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=1642498316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642498316&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.9-1-58

DO - 10.1634/theoncologist.9-1-58

M3 - Article

C2 - 14755015

AN - SCOPUS:1642498316

VL - 9

SP - 58

EP - 67

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -